Exact Sciences Corporation

BIT:1EXAS Stock Report

Market Cap: €16.7b

Exact Sciences Valuation

Is 1EXAS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of 1EXAS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: 1EXAS (€87.47) is trading below our estimate of future cash flow value (€130.95)

Significantly Below Future Cash Flow Value: 1EXAS is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1EXAS?

Key metric: As 1EXAS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 1EXAS. This is calculated by dividing 1EXAS's market cap by their current revenue.
What is 1EXAS's PS Ratio?
PS Ratio6.1x
SalesUS$3.25b
Market CapUS$19.72b

Price to Sales Ratio vs Peers

How does 1EXAS's PS Ratio compare to its peers?

The above table shows the PS ratio for 1EXAS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.2x
PHIL Philogen
10.3x-45.40%€881.8m
REC Recordati Industria Chimica e Farmaceutica
3.9x7.32%€9.9b
INCY Incyte
3.9x-1.49%US$20.1b
UTHR United Therapeutics
6.6x10.59%US$20.8b
1EXAS Exact Sciences
6.1x9.33%€19.7b

Price-To-Sales vs Peers: 1EXAS is good value based on its Price-To-Sales Ratio (6.1x) compared to the peer average (6.2x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does 1EXAS's PS Ratio compare vs other companies in the European Biotechs Industry?

53 CompaniesPrice / SalesEstimated GrowthMarket Cap
1EXAS 6.1xIndustry Avg. 7.3xNo. of Companies53PS01224364860+
53 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 1EXAS is good value based on its Price-To-Sales Ratio (6.1x) compared to the European Biotechs industry average (7.3x).

Price to Sales Ratio vs Fair Ratio

What is 1EXAS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1EXAS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6.1x
Fair PS Ratio10.5x

Price-To-Sales vs Fair Ratio: 1EXAS is good value based on its Price-To-Sales Ratio (6.1x) compared to the estimated Fair Price-To-Sales Ratio (10.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1EXAS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€87.47
€89.59
+2.43%
2.97%€99.91€88.90n/a16
Feb ’27€86.22
€90.52
+4.99%
2.97%€100.95€89.83n/a16
Jan ’27€86.60
€89.02
+2.80%
5.69%€100.47€72.37n/a16
Dec ’26€87.18
€89.34
+2.48%
4.81%€90.49€73.25n/a15
Nov ’26€55.66
€60.27
+8.28%
14.00%€85.79€45.47n/a21
Oct ’26€47.13
€55.33
+17.41%
12.17%€72.44€45.17n/a22
Sep ’26€38.50
€53.73
+39.56%
12.10%€68.26€39.25n/a23
Aug ’26€40.89
€60.04
+46.83%
10.72%€78.82€47.29n/a24
Jul ’26€46.59
€58.12
+24.75%
10.54%€76.41€45.85n/a25
Jun ’26€50.48
€60.63
+20.10%
10.39%€79.27€47.56n/a26
May ’26€39.65
€59.42
+49.89%
10.89%€75.28€46.06n/a25
Apr ’26n/a
€63.67
0%
10.80%€79.49€48.06n/a24
Mar ’26n/a
€67.22
0%
8.82%€82.01€58.17n/a23
Feb ’26n/a
€69.37
0%
10.33%€91.30€58.62€86.2223
Jan ’26n/a
€68.47
0%
11.46%€90.52€57.17€86.6021
Dec ’25n/a
€67.59
0%
9.14%€82.09€57.27€87.1821
Nov ’25n/a
€73.97
0%
11.44%€92.08€56.17€55.6621
Oct ’25n/a
€70.64
0%
10.18%€90.34€55.11€47.1321
Sep ’25n/a
€67.78
0%
11.48%€89.41€53.65€38.5021
Aug ’25n/a
€70.52
0%
11.77%€92.67€55.60€40.8920
Jul ’25n/a
€75.65
0%
12.16%€93.44€56.06€46.5921
Jun ’25n/a
€78.68
0%
9.55%€92.17€60.83€50.4820
May ’25n/a
€83.90
0%
11.25%€107.96€61.96€39.6520
Apr ’25n/a
€81.87
0%
10.86%€106.40€61.06n/a21
Mar ’25n/a
€81.87
0%
10.86%€106.40€61.06n/a21
Feb ’25n/a
€82.59
0%
11.68%€106.18€60.94n/a21
€89.59
Fair Value
2.4% undervalued intrinsic discount
16
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/18 21:53
End of Day Share Price 2026/02/18 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Exact Sciences Corporation is covered by 42 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Catherine Ramsey SchulteBaird
Luke SergottBarclays
Raymond MyersBenchmark Company